BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 6366138)

  • 1. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen.
    Bleyer WA; Coccia PF; Sather HN; Level C; Lukens J; Niebrugge DJ; Siegel S; Littman PS; Leikin SL; Miller DR
    J Clin Oncol; 1983 May; 1(5):317-25. PubMed ID: 6366138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.
    Tubergen DG; Gilchrist GS; O'Brien RT; Coccia PF; Sather HN; Waskerwitz MJ; Hammond GD
    J Clin Oncol; 1993 Mar; 11(3):520-6. PubMed ID: 8445427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failed central nervous system prophylaxis in children with acute lymphoblastic leukaemia: treatment and outcome.
    Pinkerton CR; Chessells JM
    Br J Haematol; 1984 Aug; 57(4):553-61. PubMed ID: 6589013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children.
    Freeman AI; Weinberg V; Brecher ML; Jones B; Glicksman AS; Sinks LF; Weil M; Pleuss H; Hananian J; Burgert EO; Gilchrist GS; Necheles T; Harris M; Kung F; Patterson RB; Maurer H; Leventhal B; Chevalier L; Forman E; Holland JF
    N Engl J Med; 1983 Mar; 308(9):477-84. PubMed ID: 6571946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term evaluation of a CNS prophylaxis trial--treatment comparisons and outcome after CNS relapse in childhood ALL: a report from the Childrens Cancer Study Group.
    Ortega JA; Nesbit ME; Sather HN; Robison LL; D'Angio GJ; Hammond GD
    J Clin Oncol; 1987 Oct; 5(10):1646-54. PubMed ID: 3309198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
    Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study.
    Sullivan MP; Chen T; Dyment PG; Hvizdala E; Steuber CP
    Blood; 1982 Oct; 60(4):948-58. PubMed ID: 6956376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group.
    Bleyer WA; Sather HN; Nickerson HJ; Coccia PF; Finklestein JZ; Miller DR; Littman PS; Lukens JN; Siegel SE; Hammond GD
    J Clin Oncol; 1991 Jun; 9(6):1012-21. PubMed ID: 2033414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Takeda T; Yatabe M; Utsumi J; Mimaya J; Ninomiya T; Yanai M
    Cancer; 1988 Apr; 61(7):1292-300. PubMed ID: 3278798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia: A Report from Children's Cancer Study Group.
    Nesbit ME; Sather H; Robison LL; Donaldson M; Littman P; Ortega JA; Hammond GD
    Cancer Res; 1982 Feb; 42(2):674-80. PubMed ID: 7034927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of central nervous system prophylaxis with cranial radiation and intrathecal methotrexate versus intrathecal methotrexate alone in acute lymphoblastic leukemia.
    Muriel FS; Svarch E; Pavlovsky S; Eppinger-Helft M; Braier J; Vergara B; Garay G; Kvicala R; Divito JM; Failace R; Dibar E; Jimenez E
    Blood; 1983 Aug; 62(2):241-50. PubMed ID: 6575836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective prevention of central nervous system leukemia with intrathecal methotrexate and intrathecal methotrexate, cytosine arabinoside, and hydrocortisone in childhood acute lymphocytic leukemia.
    Aur RJ; Hanna M; Sabbah R; Sackey K; Willoughby S; Atwood J
    Haematol Blood Transfus; 1990; 33():504-10. PubMed ID: 2323651
    [No Abstract]   [Full Text] [Related]  

  • 17. Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study.
    Falletta JM; Shuster JJ; Crist WM; Pullen DJ; Borowitz MJ; Wharam M; Patterson R; Foreman E; Vietti TJ
    Leukemia; 1992 Jun; 6(6):541-6. PubMed ID: 1602793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia.
    Ribeiro RC; Rivera GK; Hudson M; Mulhern RK; Hancock ML; Kun L; Mahmoud H; Sandlund JT; Crist WM; Pui CH
    J Clin Oncol; 1995 Feb; 13(2):333-8. PubMed ID: 7844594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNS prophylaxis using a triple intrathecal drug therapy without cranial irradiation in acute lymphoblastic leukaemia.
    Asfour I; Misset JL; Mathe G; Sabbour MS
    Int J Clin Pharmacol Res; 1988; 8(1):47-54. PubMed ID: 3163327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of maintenance treatment regimens for first central nervous system relapse in children with acute lymphocytic leukemia. A Pediatric Oncology Group study.
    Land VJ; Thomas PR; Boyett JM; Glicksman AS; Culbert S; Castleberry RP; Berry DH; Vats T; Humphrey GB
    Cancer; 1985 Jul; 56(1):81-7. PubMed ID: 3859359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.